We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A report published last week by the UK's Department of Health show that the country's National Health Service (NHS) could save approximately $167 million a year through more efficient prescribing of cholesterol-lowering drugs, or statins.
A Beijing court has ordered the three Chinese drugmakers to pay a $38,000 fine, apologize publicly and stop making counterfeit versions of Pfizer's blockbuster drug Viagra, a Pfizer spokesman said.
In observance of the holiday season, Daily International Pharma
Alert will not be published Monday, Jan. 1. The next issue will be published Tuesday, Jan. 2.
As
efforts to reduce the mortality rate from malaria-induced pregnancy complications appear not to be yielding positive results, an expert has recommended that every pregnant woman in malaria endemic regions receive at least two doses of effective anti-malaria drugs at early gestation period to guard against stillbirths.
Inex Pharmaceuticals Corporation announced that Protiva Biotherapeutics issued a press release Dec. 27 stating that it has filed a dismissal of its pending claims against Inex in the Superior Court of the State of California.
ThromboGenics and BioInvent International announced Dec. 28 that they have received a grant of 2 million euros from the European Union for the joint development of a new class of anti-angiogenesis agents.
Viragen and its majority-owned subsidiary, Viragen International,
Dec. 28 announced completion of a licensing agreement that grants exclusive rights to Orphan Australia to market, sell and distribute Multiferon (multi-subtype, human alpha interferon) in Australia and New Zealand.
A mass United Nations-backed measles immunization campaign is currently under way in Ethiopia, targeting more than 5.8 million children younger than 5 years old following growing fears earlier this year over the rise in new cases of the disease.
The FDA Dec. 27 approved the first generic versions of Zofran tablets, orally disintegrating tablets and oral solution, which are indicated to prevent nausea and vomiting associated with surgery, radiotherapy and cancer chemotherapy.
Giaconda Limited Dec. 28 announced that the European Patent Office has granted its patent for the combination of olsalazine and colchicine for the treatment of irritable bowel syndrome (IBS).